Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen Cilag says drug significantly reduces schizophrenia symptoms

Janssen Cilag says drug significantly reduces schizophrenia symptoms

24th May 2006

Janssen-Cilag has revealed that Paliperidone extended release (ER) “significantly” reduces positive and negative schizophrenic symptoms, according to a new study.

Paliperidone ER, marketed by Janssen-Cilag in Europe and Johnson and Johnson in the US, is an orally-administered form of risperidone that has been used to treat psychotic depression and bipolar disorder. Various doses of Paliperidone ER were administered to patients who were judged on five factors: positive symptoms, negative symptoms, disorganised thoughts, uncontrolled hostility or excitement and anxiety or depression.

The company said that the drug displayed “significant improvements” in the behaviour of the patients in comparison to those using the placebo.

David P Walling, the chief clinical officer of Collaborative NeuroScience, which was part of the investigations, said: “The results of this trial suggest both strong efficacy and good tolerability.”

“If approved by the FDA, Paliperidone ER may offer clinicians an important new treatment option with the potential to help patients control their symptoms and improve functioning,” he added.

The UK’s Mental Health Foundation estimates that one in every 100 people suffers from manic depression or schizophrenia. It says that the economic cost of schizophrenia, depression, stress and anxiety amounts to almost 12 billion pounds.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.